REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky

A securities class action has been filed against Replimune Group, Inc. for allegedly failing to disclose regulatory concerns about its RP1 trial design to shareholders. The lawsuit claims the company built its regulatory strategy around single-arm trial designs that the FDA had already questioned, including response criteria inconsistent with RECIST v1.1 standards. Investors who purchased REPL shares between October 20, 2025 and April 10, 2026 experienced significant losses, with the stock declining 84.16% during the class period.